ClinicalTrials.Veeva

Menu
S

Shaare Zedek Medical Center | The Helmsley Cancer Center - Oncological Day Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Tirzepatide
Vedolizumab
LY3298176
Guselkumab
Azacitidine
Sacituzumab
Lenalidomide
Mirikizumab
Atezolizumab

Parent organization

This site is a part of Shaare Zedek Medical Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

119 of 165 total trials

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).

Enrolling
Acute Ischemic Stroke
Biological: Redasemtide
Drug: Placebo

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting
Polycythemia Vera
Drug: Placebo
Drug: Rusfertide

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Active, not recruiting
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally...

Enrolling
Breast Cancer
Drug: Abemaciclib
Drug: Ribociclib
Locations recently updated

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

This purpose of this study is to establish proof of concept of AG-946 in participants with LR-MDS in Phase 2a and to compare the effect of AG-946 ver...

Active, not recruiting
Myelodysplastic Syndromes
Drug: AG-946
Drug: Placebo

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Carboplatin

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombin...

Enrolling
Carcinoma, Non-small-Cell Lung
Drug: Lazertinib
Drug: Direct Oral Anticoagulant (DOAC)

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Amivantamab

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety o...

Enrolling
Perianal Crohns Disease
Fistulizing Crohns Disease
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting
Advanced or Metastatic Non-small Cell Lung Cancer
Drug: Lazertinib
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Lilly logo
Pfizer logo
Takeda logo
Roche logo
Gilead Sciences logo
National Cancer Institute (NCI) logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems